Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing therapies for hypertension and related cardiometabolic disease. Its lead candidate, lorundrostat, is an aldosterone synthase inhibitor designed for patients with uncontrolled or resistant high blood pressure. The company focuses on targeting excess aldosterone as a driver of difficult-to-treat hypertension rather than adding another conventional antihypertensive class.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -43.3 | — |
| Q3 2025 | 0 | — | -36.9 | — |
| Q4 2025 | 0 | — | -32.2 | — |
| Q1 2026 | 0 | — | -39.3 | — |
| Q2 2026 | 0 | — | -241.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Alvotech (ALVO), Establishment Labs Holdings Inc. (ESTA), Sunrun Inc. (RUN), Formula Systems (1985) Ltd. (FORTY), Alamar Biosciences, Inc. (ALMR), Intuitive Machines, Inc. (LUNR)